Insider Transactions in Q2 2025 at Biomarin Pharmaceutical Inc (BMRN)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2025
|
Richard A Meier Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+4.96%
|
-
|
|
May 20
2025
|
Timothy P Walbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+40.47%
|
-
|
|
May 20
2025
|
Cristin Hubbard EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,155
-6.59%
|
$127,145
$59.93 P/Share
|
|
May 20
2025
|
Mark J Enyedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+32.92%
|
-
|
|
May 20
2025
|
Maykin Ho Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+19.19%
|
-
|
|
May 20
2025
|
Robert J. Hombach Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+13.71%
|
-
|
|
May 20
2025
|
Barbara W. Bodem Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+32.91%
|
-
|
|
May 20
2025
|
Athena Countouriotis Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+32.92%
|
-
|
|
May 20
2025
|
Willard H Dere Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+14.58%
|
-
|
|
May 20
2025
|
Elizabeth M Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+16.18%
|
-
|
|
May 20
2025
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,786
-11.19%
|
$105,374
$59.31 P/Share
|
|
May 19
2025
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
996
-5.87%
|
$58,764
$59.27 P/Share
|
|
May 02
2025
|
Cristin Hubbard EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
273
-0.83%
|
$17,472
$64.92 P/Share
|
|
Apr 30
2025
|
Cristin Hubbard EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
273
+0.82%
|
$14,742
$54.14 P/Share
|